INTRODUCTION {#sec1-1}
============

The increasing prevalence of obesity is contributing to the development of type 2 diabetes. Therefore, weight control strategies play a crucial role in the prevention and management of type 2 diabetes. As many glucose-lowering drugs cause weight gain, combination use of antidiabetic and antiobesity drugs is very common. Furthermore, most drugs are metabolized in the liver, and hepatic injury is a very common side-effect of many drugs.\[[@ref1]\]

The gastrointestinal lipase inhibitor orlistat is an antiobesity drug, which has been used for nearly two decades. It increases the likelihood of achieving clinically significant weight loss by around 20%. It has a good safety profile, and serious adverse events such as severe liver injury are rare.\[[@ref2]\]

Pioglitazone, a thiazolidinedione which is peroxisome proliferator-activated receptor (PPAR) agonist reduces insulin resistance., Troglitazone is withdrawn because it caused idiosyncratic liver failure in some cases.\[[@ref3]\] Although the evidence of liver failure of pioglitazone is less than troglitazone, however some cases of hepatic complication have been observed.\[[@ref3][@ref4]\]

To combat the dual burden of obesity and type 2 diabetes, concurrent use of pioglitazone and orlistat is expected. In many concurrent and combinational uses of two or more drugs, drug-drug interactions should be considered to prevent possible harmfulness of these drugs. As liver toxicity is a side-effect of pioglitazone, we aimed to see if *in vitro* treatment of human hepatocellular carcinoma (HepG2) cells with a combination of pioglitazone and orlistat has any effect on pioglitazone-induced liver toxicity. To the best of our knowledge, this is the first *in vitro* study showing the effect of a combination of these two drugs in comparison to the effect of each drug alone on human hepatocellar carcinoma cells.

METHODS {#sec1-2}
=======

Human hepatocellular carcinoma cells were obtained from Iranian Biological Resource Center and cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL of penicillin, and 100 U/mL of streptomycin. Cultures were maintained at 37°C in a humidified atmosphere containing 5% CO~2~ and 95% air.

MTT was used to test the viability of cells.\[[@ref5]\] HepG2 cells were seeded in 96-well plates (10,000 cells/well) in FBS-free medium for 24 h. Then cells were treated with 20 μM orlistat, 25 μM pioglitazone or combination of them. The drug concentrations were selected based on the experiments done by various concentrations of these drugs (the data are not shown) and the selected concentrations were close to the ones in clinical settings when these drugs are used in patients. Minimal concentration of dimethylsulfoxide (DMSO) (0.1% \[v/v\]) was applied to dissolve drugs. The control group did not receive any drug. After 72 h, 10 μl of MTT (0.5 mg/mL) was added to each well for 3 h. Then, culture medium was discarded, and 100 μl DMSO was added to each well. Optical density was measured at 570 nm and cell viability was expressed as a percentage of the untreated cells.

All experiments were done in the Department of Pharmacology, School of Medicine, Iran University of Medical Sciences. Each experiment was repeated at least 3 times using different cell preparations.

The ANOVA test, followed by *post-hoc* Tukey test was used to compare the groups. *P* \< 0.05 was considered as significant. SPSS version 16 (SPSS Inc., Chicago, IL, USA) was used to analyze the data.

RESULTS {#sec1-3}
=======

The mean values (±standard error of the mean) of cell viability, in the HepG2 cells are presented in [Figure 1](#F1){ref-type="fig"}. Although, 25 μM Pioglitazon, 20 μM Orlistat alone reduced viability of living cells to some extent (about 91% and 85% of control), but this was not significant (*P* \> 0.05). Combination of two drugs significantly decreased viability of cells to 55% of control (*P* \< 0.001).

![Comparison viability of cells between groups treated with 25 μM Pioglitazon (Pio), 20 μM Orlistat (Orl) or combination of the same concentrations of two drugs. Results are expressed as the mean of three experiments (\*\*\**P* \< 0.001)](IJPVM-6-16-g001){#F1}

DISCUSSION {#sec1-4}
==========

Several drugs are used for treatment of diabetic-related hyperglycemia and obesity. One of the problems in these patients is liver disorders. Therefore the effect of drugs on liver function in these patients is important. Despite poor absorption, orlistat can cause hepatotoxicity.\[[@ref6]\] Orlistat-induced hepatotoxicity risk is higher when orlistat consume with other toxic drugs.\[[@ref7]\] In the present study, concomitant use of orlistat and pioglitazone, increased the percentage of HepG2 cell death, although each drug decreased the viability of the HepG2 cells to some extent. Existence of PPARγ in HepG2 has been confirmed. Both pioglitazon and orlistat are agonists for this receptor,\[[@ref7][@ref8][@ref9]\] and there is the probability of synergism effect of these drugs. Although increasing these drugs dose may decrease the cell viability significantly, but in the concentrations used in our experiment, which are close to the concentrations when they used in human, they were not toxic to the cells in a significant manner.

In this study, we used HepG2 cells to assess the liver toxicity of orlistat and pioglitazone as an *in vitro* model. The gold standard for drug metabolism and toxicity studies is use of human primary hepatocytes,\[[@ref10]\] but the limited availability of human liver samples, short life span and inter-donor differences limit their use for *in vitro* screening assays.\[[@ref11]\] Immortalized cell lines, in particular HepG2 cells with their unlimited life span are commonly used as an alternative to primary cells.\[[@ref12]\]

CONCLUSIONS {#sec1-5}
===========

In summary, the results showed that although pioglitazone and orlistat were not toxic to HepG2 cells *in vitro*, their combination use would decrease the viability of cells significantly. As the HepG2 cell line is derived from HepG2, the cells could be used as a model for studying the hepatoxicity of drugs in the human. Based on the previous reports, we can extrapolate the human hepatoxicity of drugs in this model. Although there are some differences between *in vivo* and *in vitro* conditions, we could conclude that the combination of orlistat and pioglitazone may cause hepatotoxicity when they are used concurrently in patients. Of course, this is a preliminary work and more studies should be done to confirm these results. This suggests that the combination of pioglitazone and orlistat could increase liver toxicity of them and it is advised that concurrent use of them be avoided especially in patients with history of liver dysfunction.
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